Andrew R. Clark
Andy is a recognized expert in respiratory drug development, with 30+ years experience in managing the development of some of the pharmaceutical industry’s most novel inhalation products; Pulmozyme (the first inhaled protein), Exubera (the first inhaled insulin) and Tobi Pohaler (the first inhaled dry powder antibiotic). His experience includes: CTO and site head at Novartis’ pulmonary drug development site in San Carlos, CA, Chief Technical Officer at Inhale/Nektar Therapeutics, General Manager and a Director of Bradford Particle Design, Head of the pulmonary product development group at Genentech, and Section Head of Respiratory Physics at Fisons Pharmaceuticals. In 1993 Andy received the young investigator award from the International Society for Aerosols in Medicine, in 2003 the TT Mercer award from the American Association for Aerosol Research and in 2012 the Charles Thiel award from Virginia Commonwealth University's Respiratory Drug Delivery organization; each for excellence and outstanding contributions in inhalable materials and aerosol science. Andy holds a Ph.D. in aerosol science from Loughborough University of Technology in the U.K.